Delcath Systems, Inc. (NASDAQ:DCTH) Shares Bought by Palisades Investment Partners LLC

Palisades Investment Partners LLC grew its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 13.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,327 shares of the company's stock after purchasing an additional 19,671 shares during the period. Palisades Investment Partners LLC owned approximately 0.53% of Delcath Systems worth $2,039,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Quarry LP acquired a new position in Delcath Systems during the fourth quarter worth $34,000. Quantbot Technologies LP acquired a new stake in shares of Delcath Systems in the fourth quarter valued at $66,000. Boothbay Fund Management LLC raised its stake in shares of Delcath Systems by 30.2% in the fourth quarter. Boothbay Fund Management LLC now owns 34,749 shares of the company's stock valued at $418,000 after acquiring an additional 8,061 shares in the last quarter. Riverwater Partners LLC raised its stake in shares of Delcath Systems by 46.2% in the fourth quarter. Riverwater Partners LLC now owns 27,229 shares of the company's stock valued at $328,000 after acquiring an additional 8,601 shares in the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in shares of Delcath Systems in the fourth quarter valued at $123,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Stock Performance

DCTH traded up $0.29 during trading on Tuesday, reaching $16.40. The company's stock had a trading volume of 353,702 shares, compared to its average volume of 372,093. Delcath Systems, Inc. has a 52-week low of $6.33 and a 52-week high of $18.23. The company's fifty day moving average price is $13.10 and its 200-day moving average price is $13.03. The company has a market capitalization of $570.97 million, a price-to-earnings ratio of -12.14 and a beta of 0.72.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The company had revenue of $19.80 million for the quarter, compared to analyst estimates of $16.83 million. Equities analysts predict that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DCTH shares. HC Wainwright reiterated a "buy" rating and issued a $29.00 price objective (up from $24.00) on shares of Delcath Systems in a research note on Friday. Wall Street Zen raised Delcath Systems from a "buy" rating to a "strong-buy" rating in a report on Saturday. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Delcath Systems currently has an average rating of "Buy" and a consensus price target of $24.00.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.